Danaher (DHR) · Life Sciences
Danaher Q2 2026 earnings: summary, key numbers & outlook
Results filed 21 Jul 2026 · Quarter ended 26 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Danaher closed its Masimo acquisition earlier than expected and agreed to buy StatLab, while bioprocessing orders grew mid-teens despite customer project timing delaying revenue.
Danaher completed its Masimo acquisition earlier than anticipated, adding a major new business to its life sciences and diagnostics portfolio. Bioprocessing orders grew mid-teens even though customer project timing held back revenue, and the Life Sciences businesses had their strongest quarter in several years. In Diagnostics, respiratory testing remained a swing factor, so Danaher now reports growth with and without it. Leica Biosystems also announced a deal to buy StatLab.
Management expects to exit 2026 at a mid-single-digit core revenue growth rate, helped by end-market recovery and recent growth initiatives. Next steps include integrating Masimo, closing StatLab by the end of 2026 and supporting expected onshoring-driven capacity expansion at Cytiva. The main tension is that the recovery is not yet broad. Management said it needs a more constructive view of academic funding before calling an inflection point, and flu-driven respiratory demand remains unpredictable.
No call transcript for this quarter, so this summary also draws on: Webull ↗.
Key numbers
- Revenue · GAAP
- $6.3 billion
- Net earnings · GAAP
- $870 million
- Diluted EPS · GAAP
- $1.23
- Adjusted diluted EPS · non-GAAP
- $1.94
- Operating profit · GAAP
- 1.1B
- Operating cash flow · GAAP
- $1.5 billion
- Free cash flow · non-GAAP
- $1.3 billion
up 5.5% year-over-year
up 60% year-over-year
up 60% year-over-year
grew 8.0%
| Segment or metric | Value | Change |
|---|---|---|
| Biotechnology core sales growth | 2.5% | |
| Life Sciences core sales growth | 5.5% | |
| Diagnostics core sales growth | 2.0% | |
| Diagnostics core sales growth excluding respiratory testing | 5.0% | |
| Total company core sales growth excluding respiratory testing | 4.5% |
Where each number comes from
- Revenue: “Revenues increased 5.5% year-over-year to $6.3 billion.”
- Net earnings: “Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.”
- Diluted EPS: “Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.”
- Adjusted diluted EPS: “Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94.”
- Operating profit: “Research and development expenses | (412) | (403) | (799) | (782) Operating profit | 1,127 | 760 | 2,471 | 2,034”
- Operating cash flow: “Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion.”
- Free cash flow: “Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion.”
- Biotechnology core sales growth: “Core sales growth (non-GAAP) | 3.0% | 2.5% | 5.5% | 2.0% Impact of respiratory testing | 1.5% | 3.0%”
- Life Sciences core sales growth: “Core sales growth (non-GAAP) | 3.0% | 2.5% | 5.5% | 2.0% Impact of respiratory testing | 1.5% | 3.0%”
- Diagnostics core sales growth: “Core sales growth (non-GAAP) | 3.0% | 2.5% | 5.5% | 2.0% Impact of respiratory testing | 1.5% | 3.0%”
- Diagnostics core sales growth excluding respiratory testing: “Impact of respiratory testing | 1.5% | 3.0% Core sales growth excluding respiratory testing (non-GAAP) | 4.5% | 5.0%”
- Total company core sales growth excluding respiratory testing: “non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $6.3B | +5.5% | +5.3% |
| Operating income | $1.1B | +48.3% | −16.1% |
| Net income | $870.0M | +56.8% | −15.5% |
| Diluted EPS | $1.23 | +59.7% | −15.2% |
| Free cash flow | $1.3B | +16.1% | +16.6% |
| Gross margin | 57.6% | −1.7 pts | −2.7 pts |
| Operating margin | 18.0% | +5.2 pts | −4.6 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Core revenue growth | third quarter of 2026 | 2.0% to 3.0% |
| Core revenue growth | full year 2026 | 3.0% to 4.0% |
| Adjusted diluted EPS | full year 2026 | $8.45 to $8.60 |
| Adjusted operating profit margin | third quarter of 2026 | ~26.5% |
| Effective tax rate | full year 2026 | ~17.0% |
Key takeaways
Masimo acquisition closed ahead of schedule
Danaher completed the Masimo acquisition earlier than it anticipated, and management expects it to be immediately accretive both strategically and to adjusted EPS. The deal gives Danaher a new large business to integrate while it is also adding bolt-ons.
Bioprocessing orders grew mid-teens despite project timing
Customer project timing weighed on bioprocessing revenue, but orders grew mid-teens, which points to demand that has not yet turned into sales. Management also expects Cytiva to support capacity expansion as onshoring accelerates, describing the start of a multi-year capex cycle.
Leica Biosystems agrees to acquire StatLab
StatLab makes products across the core histology workflow, from specimen collection through slide staining. It has more than 85% recurring revenue and complements Leica's oncology instruments, with closing expected by the end of 2026.
Diagnostics now reported with and without respiratory testing
Danaher introduced a core growth measure that excludes respiratory testing, because flu severity is outside management's control and can obscure underlying trends. Diagnostics growth was 2.0% including respiratory testing and 5.0% excluding it, and management cited menu expansions such as the multiplex GI panel and increased automation at Beckman.
Management targets mid-single-digit growth exit rate
Danaher expects to exit 2026 at a mid-single-digit core revenue growth rate, citing end-market recovery and recent growth initiatives. Beckman's China declines began to moderate as pricing stabilized, but academic funding is not yet strong enough for management to call an inflection.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $6.5B * |
| Q1 2025 | $5.7B |
| Q2 2025 | $5.9B |
| Q3 2025 | $6.1B |
| Q4 2025 | $6.8B * |
| Q1 2026 | $6.0B |
| Q2 2026 | $6.3B |
| Q3 2026 | $6.6B |
Data
| Q1 2025 | $1.32 |
| Q2 2025 | $0.77 |
| Q3 2025 | $1.27 |
| Q1 2026 | $1.45 |
| Q2 2026 | $1.23 |
| Q3 2026 | $1.75 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 21.8% |
| Q1 2025 | 22.2% |
| Q2 2025 | 12.8% |
| Q3 2025 | 19.1% |
| Q4 2025 | 22.0% |
| Q1 2026 | 22.6% |
| Q2 2026 | 18.0% |
| Q3 2026 | 19.0% |
Data
| Q4 2024 | $1.5B |
| Q1 2025 | $1.1B |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.4B |
| Q4 2025 | $1.7B |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.6B |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is Danaher's main strategic move this quarter?
Danaher completed its Masimo acquisition earlier than anticipated and expects it to be immediately accretive. Leica Biosystems also announced its intention to acquire StatLab, which is expected to close by the end of 2026.
How is bioprocessing demand trending?
Orders grew mid-teens even though customer project timing held back bioprocessing revenue. Management also expects Cytiva to support capacity expansion as onshoring activity accelerates.
Why is Danaher reporting growth excluding respiratory testing?
Respiratory testing demand depends on flu severity, which management does not control, and combining it with other Diagnostics revenue can obscure underlying growth. Core growth excluding respiratory testing was 4.5% for the company in the quarter.
What is StatLab and why is Leica Biosystems buying it?
StatLab makes products across the core histology workflow, from specimen collection through slide staining, with more than 85% recurring revenue and about $250M of 2025 revenue. It complements Leica Biosystems' oncology instrument portfolio, and Danaher expects high-single-digit long-term core growth from it.
What are the main risks to Danaher's recovery thesis?
Management said it needs a more constructive view of academic funding before calling an inflection point. Respiratory testing demand is also volatile, and the release flags tariffs and Masimo integration and debt as risks.
Documents
SEC filing